File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jhealeco.2010.06.007
- Scopus: eid_2-s2.0-77956182757
- PMID: 20656362
- WOS: WOS:000282250700011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Is newer always better? Re-evaluating the benefits of newer pharmaceuticals
Title | Is newer always better? Re-evaluating the benefits of newer pharmaceuticals |
---|---|
Authors | |
Keywords | Drug offsets Health care costs Prescription drugs |
Issue Date | 2010 |
Citation | Journal of Health Economics, 2010, v. 29, n. 5, p. 743-750 How to Cite? |
Abstract | Whether newer pharmaceuticals justify their higher costs by reducing other health expenditures has generated significant debate. We replicate a frequently cited paper by Lichtenberg on drug "offsets" and find the results disappear using a more appropriate model or updated dataset. Further, we test the suitability of similar methods using newer hypertension drugs. We find our observational results run counter to well-established clinical evidence on comparative efficacy and conclude that our model, as well as other studies that do not adequately control for unobserved characteristics that jointly determine drug choice and health expenditures, are likely subject to significant bias. © 2010 Elsevier B.V. |
Persistent Identifier | http://hdl.handle.net/10722/280766 |
ISSN | 2023 Impact Factor: 3.4 2023 SCImago Journal Rankings: 2.444 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Law, Michael R. | - |
dc.contributor.author | Grépin, Karen A. | - |
dc.date.accessioned | 2020-02-17T14:34:53Z | - |
dc.date.available | 2020-02-17T14:34:53Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Journal of Health Economics, 2010, v. 29, n. 5, p. 743-750 | - |
dc.identifier.issn | 0167-6296 | - |
dc.identifier.uri | http://hdl.handle.net/10722/280766 | - |
dc.description.abstract | Whether newer pharmaceuticals justify their higher costs by reducing other health expenditures has generated significant debate. We replicate a frequently cited paper by Lichtenberg on drug "offsets" and find the results disappear using a more appropriate model or updated dataset. Further, we test the suitability of similar methods using newer hypertension drugs. We find our observational results run counter to well-established clinical evidence on comparative efficacy and conclude that our model, as well as other studies that do not adequately control for unobserved characteristics that jointly determine drug choice and health expenditures, are likely subject to significant bias. © 2010 Elsevier B.V. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Health Economics | - |
dc.subject | Drug offsets | - |
dc.subject | Health care costs | - |
dc.subject | Prescription drugs | - |
dc.title | Is newer always better? Re-evaluating the benefits of newer pharmaceuticals | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.jhealeco.2010.06.007 | - |
dc.identifier.pmid | 20656362 | - |
dc.identifier.scopus | eid_2-s2.0-77956182757 | - |
dc.identifier.volume | 29 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 743 | - |
dc.identifier.epage | 750 | - |
dc.identifier.isi | WOS:000282250700011 | - |
dc.identifier.issnl | 0167-6296 | - |